Poolbeg Pharma (LON:POLB – Get Free Report)‘s stock had its “house stock” rating reissued by equities researchers at Shore Capital Group in a note issued to investors on Monday,London Stock Exchange reports.
Poolbeg Pharma Price Performance
POLB opened at GBX 7.40 on Monday. The firm has a market cap of £52.18 million, a price-to-earnings ratio of -7.87 and a beta of 1.81. Poolbeg Pharma has a 1 year low of GBX 2.50 and a 1 year high of GBX 9. The stock’s 50 day simple moving average is GBX 6.35 and its 200 day simple moving average is GBX 5.07.
Poolbeg Pharma (LON:POLB – Get Free Report) last issued its earnings results on Tuesday, April 28th. The company reported GBX (0.94) EPS for the quarter. As a group, sell-side analysts anticipate that Poolbeg Pharma will post -0.68 EPS for the current year.
About Poolbeg Pharma
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.
Featured Articles
- Five stocks we like better than Poolbeg Pharma
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
